Strategic partnerships OBT has a strong track record of multi-year collaborations with top pharma players (Boehringer Ingelheim, ImmunoGen, Kite Pharma, Bristol Myers Squibb, Roche). Leverage these existing relationships to co-develop or license novel IO and ADC assets, and explore expansion opportunities with partners seeking first-in-class targets or OGAP verified programs.

Clinical stage momentum Lead asset OBT076 ADC in Phase 1b with a dual mechanism suggests potential for alliance in late-stage development or staged co-investment. Target partners seeking near-term IO/ADC clinical programs to bolster their oncology pipelines and de-risk early-stage assets through collaboration.

OGAP platform value OGAP Verify expands target discovery and de-risking of target validity. Position OGAP as a differentiator for partners aiming to accelerate discovery of novel T-cell engagers and IO/ADC programs, offering a competitive edge in target selection and translational proof.

Global expansion OBT operates across the UK and North America with clinics or development activities in the US and Europe. Highlight opportunities for cross-border co-development deals, regional manufacturing access, and shared clinical trial infrastructure to accelerate global trials.

Financial and growth signals Revenue range indicates a scale-up phase with ongoing high-value partnerships. Target potential licensing, milestone, or co-development deals that align with the company’s growth trajectory and enable faster portfolio expansion without immediate large capital outlays.